期刊文献+

屎肠球菌Hyl蛋白的免疫保护性研究 被引量:1

Immunoprotection of Enterococcus faecium hyaluronidase protein in mice
下载PDF
导出
摘要 目的用基因工程方法获得屎肠球菌类透明质酸酶(Hyalronidase,Hyl)蛋白,经口服免疫小鼠后,探讨机体产生的免疫应答和抗感染保护作用。方法Hyl用Ni2+-NTA柱纯化后,作为抗原给小鼠灌胃进行免疫,ELISA检测小鼠血清IgG、IgA、小肠粘液sIgA和粪便sIgA。并用屎肠球菌TX0016腹腔攻击已免疫的小鼠,观察其免疫保护性。结果重组蛋白经Ni2+-NTA柱纯化后,灌胃免疫小鼠后。ELISA检测结果血清IgA、IgG,粪sIgA,肠粘液sIgA明显高于对照组(P<0.01)。通过细菌攻击后,小鼠的平均存活时间也明显长于对照组。结论重组蛋白Hyl经口服免疫可有效诱导粘膜免疫应答,产生高水平的sIgA,发挥局部粘膜免疫作用和抗菌保护作用。Hyl有望作为预防屎肠球菌口服疫苗的候选抗原。 To obtain the recombinant hyaluronidase(Hyl) protein of E. faefium by gene-engineering, the immune response in mice orally fed with Hyl protein and the immunoprotection of anti-infection immunity were investigated. The recombinant protein was purified by Ni^2+ -NTA agarose and fed to mice by oral immunization. The change of antigen-specific antibody in the serum, mucosal fluid and faces were detected by ELISA assay, and the protective role of anti-bacterial immunity was evaluated after infection with E. faecium TX0016. The results showed that antigen-specific antibody was higher than controls as demonstrated by ELISA, and the average survival time was longer than controls too, after infection with TX0016. It concludes that the Hyl protein can induce effective mucosal immune response and produce higher levels of slgA after oral immunization with Hyl protein. The recombinant fusion protein Hyl can be used as an oral vaccine antigen for prevention of E. faecium infection.
出处 《中国人兽共患病学报》 CAS CSCD 北大核心 2007年第9期913-915,共3页 Chinese Journal of Zoonoses
基金 国家自然科学基金资助项目(30475995)
关键词 屎肠球菌 透明质酸酶 口服免疫 特异性抗体 Enterococcus faecium Hyaluronidase oral immunization specific antibody
  • 相关文献

参考文献9

  • 1Hynes WL,Walton SL.Hyaluronidase of Gram-positive bacteria[J].FEMS Microbiol letter,2000;183:201-207.
  • 2Berry AM,Paton JC.Addictive attenuation of virulence of Streptococcus pneumonia by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins[J].Infect and Immun,2000;68:133-140.
  • 3Rice LB,Carias L,Rudin S,et al.A potential virulence gene,hylEfm,predominates in Enterococcus faecium of clinical origin[J].J Infect Dis,2003;187(3):508-12.
  • 4吴利先,杨致邦,林珊珊,刘淼.幽门螺杆菌HpaA-CtxB融合蛋白的表达及其免疫原性研究[J].中国免疫学杂志,2004,20(5):306-310. 被引量:5
  • 5FM 奥斯伯,RE 金斯顿,JG 塞德曼,等.精编分子生物学实验指南[M].北京:科学出版社,1998:415-424.
  • 6Herve Dupont,Philippe Montravers,Jacqueline Mohler,et al.Disparate Findings on the role of virulence Factors of Enterococcus faecalis in mouse and rat models of peritonitis[J].Infect Immun,1998,66(6):2570-2575.
  • 7Jones RN.Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients[J].Am J Med,1996,100(6):3-12.
  • 8Donald EL,Keller N,Barth A,et al.Clinical prevalence antimicrobial susceptibility and geographic resistance patterns of Enterococci:results from the SENTRY antimicrobial surveillance program,1997-1999[J].Clinical Infections Diseases,2001,32(l2):133-145.
  • 9Huycke,MM,Sahm DF,Gimore MS.Multiple-drug resistant enterococci:the nature of the problem and am agenda for the future[J].Emerg Infect Dis,1998,4:239-249.

二级参考文献13

  • 1赖燕来,高杰英.用BA-ELISA斑点法检测痢疾杆菌免疫小鼠GALT中的特异性抗体分泌细胞(ASC)[J].中国免疫学杂志,1995,11(5):280-282. 被引量:12
  • 2Hocking D,Webb E,Redcliff F et al.Isolation of recombinant protective Helicobacter Pylori antigen[J].Infect Immun,1999;67(9):4713-4719.
  • 3International agency for research on cancer.Schistosomes,liver fluker and Helicobacter Pylori[J].IARC monographs on the evalition on carcinogenic risks to human,1994;61:177-240.
  • 4Pounder R E,Ng D.The prevalence of Helicobacter Pylori infection in different countries[J].Science,1995;267:17.
  • 5Evans D G,Evans D J Jr,Lampert H C et al.Restriction fragment length polymorphism in the adhesion gene HpaA of Helicobacter Pylori [J].Am J Gastroenterol,1995;90(8):1282-1288.
  • 6Chikubo K,Isaka M,Yasuda Y et al.Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-adminnisterad bovine serum albumin[J].Vaccine,1998;16(1):150-155.
  • 7Wu bong-ying,Russel M W.Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant[J].Vaccine,1998;16(2):286-292.
  • 8Luffeld R J,Fijen C A.Antibiotic resistance of Helicobacter Pylori:a cross-sectional study in consecutive patients and relation to ethnicity[J].Clin Microbiol Infect,2003;9(7):600-604.
  • 9Rerksuppaphol S,Hardikar W,Midolo P et al.Antimicrobial resistance in Helicobacter Pylori isolates from children[J].J Paediatr Child Health,2003;39(5):332-335.
  • 10Du R J,Ho B.Surface localized Heat Shock Protein 20(HSLV) of Helicobacter Pylori[J].Helicobacter,2003;8(4):257-267.

共引文献4

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部